Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
26 Julho 2023 - 8:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced that it will host a conference
call and webcast on Wednesday, August 2, 2023, at 8:00
a.m. ET to discuss results for the second quarter 2023 and to
provide a corporate update.
To access the conference call:
- U.S. callers should dial +1-877-407-0989 and international
callers should dial +1-201-389-0921 approximately five minutes
before the call begins.
- Participants should ask to be connected to the Editas Medicine
Earnings Conference Call.
The conference call will also be webcast and can be accessed
from the “Investors” section of the Editas Medicine website at
https://www.editasmedicine.com. A replay will be available at the
same site approximately one hour after the completion of the
call.
About Editas MedicineAs a
clinical-stage genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas12a and
Cas9 genome editing systems into a robust pipeline of treatments
for people living with serious diseases around the world. Editas
Medicine aims to discover, develop, manufacture, and commercialize
transformative, durable, precision genomic medicines for a broad
class of diseases. Editas Medicine is the exclusive licensee of
Broad Institute’s Cas12a patent estate and Broad Institute and
Harvard University’s Cas9 patent estates for human medicines. For
the latest information and scientific presentations, please visit
www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024